Charles Link

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Part of Lumos Pharma, Inc., BioProtection Systems Corp. is a company that manufactures biological products. The company is based in Ames, IA.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL.

QSAM Biosciences, Inc. engages in the provision of nuclear medicines for the treatment of cancer and related diseases and conditions. It also focuses on the development of its licensed radiopharmaceutical drug candidate, Samarium-153-DOTMP or CycloSam. The company was founded by Christopher M. Nelson, Douglas R. Baum and C. Richard Piazza on August 26, 2004 and is headquartered in Austin, TX.

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.